Leo Pharma A/S

Address: Industriparken 55

Sponsor Overview

assignment

Specializations

Atopic Dermatitis and Atopic Hand Eczema

Leo Pharma A/S focuses on inflammatory skin disease research centered on atopic dermatitis, including moderate-to-severe disease in adults, children, and infants. Its portfolio also includes work in atopic hand eczema, reflecting interest in difficult-to-treat eczematous conditions with substantial symptom burden and impact on daily function.

Moderate-to-severe atopic dermatitis
Atopic hand eczema
Paediatric and infant skin disease
Itch, scratching, and skin barrier function

Research activity in this area includes biologic and topical approaches aimed at controlling skin inflammation, improving lesion extent and symptom severity, and addressing quality-of-life effects in younger patients and caregivers.

Psoriasis and Palmoplantar Pustulosis

The sponsor has active interest in chronic psoriatic disease, including moderate-to-severe plaque psoriasis in people with high body weight and mild to severe palmoplantar pustulosis. These studies indicate a therapeutic emphasis on inflammatory dermatoses that can be persistent, functionally limiting, and difficult to manage on the hands and feet.

Moderate-to-severe plaque psoriasis
Palmoplantar pustulosis
High body weight psoriasis populations
Chronic inflammatory skin disorders

This area includes evaluation of treatment approaches for patients with substantial skin involvement and special clinical characteristics relevant to response in psoriasis.

Gout Flare and Autoinflammatory Disease

Leo Pharma A/S also funds research in acute gout flares, extending its therapeutic interests beyond dermatology into inflammatory pain and crystal-associated disease. The trial landscape suggests attention to autoinflammatory mechanisms and treatment options for sudden inflammatory episodes.

Gout flares
Acute inflammatory pain
Autoinflammatory disease
Pharmacokinetic characterization

Work in this domain reflects interest in therapies for episodic inflammation and conditions where rapid symptom control is clinically important.

Paediatric Dermatology

A substantial part of the sponsor’s research activity is directed toward children and infants with inflammatory skin disease, particularly moderate-to-severe atopic dermatitis. These studies address disease control across early life stages and the burden placed on family routines and well-being.

Children with atopic dermatitis
Infant skin disease
Topical corticosteroid combination treatment
Quality of life in paediatric care

Research in this field includes evaluation of skin symptoms, itching, and caregiver-relevant outcomes in younger populations with chronic inflammatory dermatoses.

Sponsored Trials

Trial Name	Country	Status
A phase 2b, randomised, double-blind, placebo-controlled, multi-site, parallel-group, dose finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered LEO 138559 in adult subjects with moderate-to-severe atopic dermatitis (AD)	Czechia France Germany Hungary Poland Romania Spain	Not Recruiting
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)	Belgium Czechia France Germany Poland Portugal Spain Sweden The Netherlands	Not Recruiting
Comparison of Adjustable Versus Standard Brodalumab Dosage Regimens in Patients with Moderate-to-Severe Plaque Psoriasis and Body Weight ≥120 kg	Belgium Czechia France Germany Greece Hungary Italy Poland Spain	Not Recruiting
Efficacy and Safety Evaluation of Delgocitinib Cream Versus Vehicle in Adult Patients with Mild to Severe Palmoplantar Pustulosis: A Phase 2a, Double-Blind Trial	Germany Poland	Recruiting
Effisayil® REP: An open-label, multicenter, single-arm, post-marketing trial (in select countries) to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis (GPP) presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v.	Belgium France Germany Italy Spain	Not Recruiting
Evaluation of Spesolimab Efficacy and Safety in Adult Patients with Ulcerative Pyoderma Gangrenosum: A Randomized, Double-Blind, Placebo-Controlled Trial	Austria Belgium Finland France Germany Italy Norway Poland Portugal Spain Sweden	Recruiting
Investigation of LEO 158968 on Pharmacokinetics, Safety, and Tolerability in Patients with Gout Flares	France The Netherlands	Not Recruiting
Long-term Safety and Efficacy Evaluation of Spesolimab in Patients with Generalized Pustular Psoriasis Following Prior Spesolimab Trials	Belgium France Germany Italy Spain	Not Recruiting
Pharmacokinetics and Safety Evaluation of Tralokinumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized, Assessor-Blinded Study	Czechia France Spain The Netherlands	Not Recruiting
Phase 3 Double‑Blind Vehicle‑Controlled Trial of Topical Delgocitinib Cream in Adult Women with Lichen Sclerosus: 12‑Week Efficacy and 40‑Week Safety Evaluation	France Germany Italy Poland Spain	Not Yet Recruiting